2026-04-13T01:31:01Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1742602025-12-04T19:12:02Zcom_2072_1057col_2072_478858col_2072_478917col_2072_478921

00925njm 22002777a 4500 dc Griguolo, Gaia author Brasó Maristany, Fara author González Farré, Blanca author Pascual, Tomás author Chic Ruché, Núria author Saurí, Tamara author Kates, Ronald author Gluz, Oleg author Martínez, Débora author Paré, Laia author Tsvetkova, Vassilena author Pesantez, David author Vidal Losada, Maria Jesús author Adamo, Barbara author Muñoz Mateu, Montserrat author Galván, Patricia author Barberá, Laura author Cuatrecasas Freixas, Miriam author Christgen, Mathias author Kreipe, Hans author Monge Escartín, Inés author Villagrasa, Patricia author Soy Muner, Dolors author Giarratano, Tommaso author Dieci, Maria Vittoria author Conte, Pierfranco author Harbeck, Nadia author Guarneri, Valentina author Prat Aparicio, Aleix author 2021-02-24T16:59:37Z 2021-02-24T16:59:37Z 2020-07-14 2021-02-24T16:59:37Z Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA.We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed para n-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally, Càncer de mama Receptors d'hormones Breast cancer Hormone receptors ERBB2mRNA expression and response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-positive breast cancer